Skip to search formSkip to main contentSkip to account menu

LAF 237

Known as: LAF-237, LAF237 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
Dipeptidyl peptidase (DPP) IV inhibitors are probably beneficial for preventing diabetic complication and modulating glucagon… 
2012
2012
Aim. To investigate the combination effects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237 (DPP… 
Highly Cited
2011
Highly Cited
2011
Fibroblast activation protein-α (FAP) is a cell surface, serine protease of the post-prolyl peptidase family that is expressed in… 
Highly Cited
2008
Highly Cited
2008
LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] is an inhibitor of dipeptidyl peptidase IV that delays the… 
Review
2006
Review
2006
  • A. Barnett
  • International journal of clinical practice
  • 2006
  • Corpus ID: 2645092
The dipeptidyl peptidase 4 (DPP‐4) inhibitors enhance the body's own ability to control blood glucose by increasing the active… 
Highly Cited
2005
Highly Cited
2005
Objective:  A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the… 
Highly Cited
2004
Highly Cited
2004
This study characterizes the high-fat diet-fed mouse as a model for impaired glucose tolerance (IGT) and type 2 diabetes. Female… 
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with… 
Highly Cited
2004
Highly Cited
2004
The stimulation of insulin vs. inhibition of glucagon secretion in relation to the antidiabetic action of glucagon-like peptide-1…